Prof Ranjit Manchanda

Prof Wolfson Institute of Population Health, QMUL; Consultant Gynae-Oncologist Barts Health NHS Trust; Hon Prof LSHTM; Precision Prevention in Women’s Cancers

[ISRCTN: the UK's Clinical Study Registry @ISRCTN]

A population-based digital study offering people testing for cancer genes, to identify people at increased risk of cancer so they can take steps to prevent it or detect it early. The PROTECT-C Study registered at #ISRCTN by @ProfManchanda

https://t.co/EZEA7gFSlu

#clinicaltrials

[Prof Ranjit Manchanda @ProfManchanda]

@

[Prof Ranjit Manchanda @ProfManchanda]

https://t.co/kAs0L1q8BK

Good to see the coverage of the NHS JBRCA programme in the JC, highlighting its importance, outreach and benefit. Thx to the huge number of community and professional stakeholders who have supported it. thx to NHSE for the continued support.

[Prof Ranjit Manchanda @ProfManchanda]

@QMUL @QMBCI @QMUL_WIPH @wpp_wiph @eveappeal @OvarianCancerUK @TargetOvarian @Ovacome @BreastCancerNow @PreventBC

[Women's Precision Prevention @wpp_wiph]

A great time was had by the #WPP_team at our 2025 Christmas party! There have been many wonderful achievement this year; with PhDs, clinical fellowships, Grants, publications and much more to celebrate!
Many thanks to Ranjit Manchanda and to Vic White for organising the party.

[Prof Ranjit Manchanda @ProfManchanda]

@QMUL @QMBCI @QMUL_WIPH @wpp_wiph

[Prof Ranjit Manchanda @ProfManchanda]

Good to see our paper finally out
Important implications for guidelines and clinical practice
This can shorten the diagnostic pathway
@eveappeal @BAGPGynPath @BGCS_org @EngageEsgo @ESGO_society @Ovacome @TargetOvarian @OvarianCancerUK @ENYGO_official @ovarcome @IGCSociety

[Women's Precision Prevention @wpp_wiph]

Our paper ‘Consent model for tumour genetic testing in ovarian cancer’ shows strong support for reflex tumour genetic testing. Most patients, physicians, and charity representatives favoured testing without explicit consent, alongside an opt-out option. https://t.co/VCMQOkx5mW

[Prof Ranjit Manchanda @ProfManchanda]

Well done Priyanka
Onwards and upwards

[Women's Precision Prevention @wpp_wiph]

Congratulations to our WPP member Priyanka Deshmukh on being awarded PPI grant of £966 from the QMUL Centre for Public Engagement. This PPI work will help inform the design of a future project ‘LEGACY – Lynch Evaluation for Genetic Analysis and Cascade testing in Years past’.

[The British Assoc of Gynaecological Pathology @BAGPGynPath]

Please join us for our monthly webinar on Wed 17th December at 3 pm UK time. This month's topic is a session on 'New Entities Identified Through Referral Practice' with Prof Glenn McCluggage. Free to register @ https://t.co/mWdwBiPq4J #PathTwitter #GynPath #Gynaepath

[Women's Precision Prevention @wpp_wiph]

@ProfManchanda speaks at the 9th European Tumour Hereditary Group meeting held in Heidelberg in September. He had a keynote presentation on population screening strategies and implications of the PROTECTOR study and presented abstracts of findings from our PRESCORES study.

[Prof Ranjit Manchanda @ProfManchanda]

New validated and accurate model(s) are necessary for predicting surgical morbidity in women undergoing cytoreductive ovarian cancer surgery.
@QMUL_WIPH @QMUL_WIPH_CPDD @BGCS_org @BAGPGynPath @ESGO_society @Ovacome @TargetOvarian @OvarianCancerUK @eveappeal @wpp_wiph

[Prof Ranjit Manchanda @ProfManchanda]

https://t.co/MYBhnj8drb
Great to see our paper out on PPOSSUM score for predicting morbidity in Ovarian cancer cytoreductive surgery.
We show it is a poor predictor and should not be used.

[Prof Ranjit Manchanda @ProfManchanda]

@QMUL @NHSBartsHealth @QMUL_WIPH @QMUL_WIPH_CPDD @wpp_wiph @BAGPGynPath @BGCS_org @eveappeal @OvarianCancerUK @TargetOvarian @OvCancerDay @Ovacome @ovarcome @Barts_Charity @RosetreesT @IGCSociety @EngageEsgo @ESGO_society @ENYGO_official @BRCAchatter

[Prof Ranjit Manchanda @ProfManchanda]

https://t.co/wd7Ax1vVyV
Great to see our paper on Risk Reducing Early Salpingectomy out in JAMA Network Open.
We describe our study design for extension of PROTECTOR to address the issue of ovarian cancer risk reduction from RRES.

[Prof Ranjit Manchanda @ProfManchanda]

Our estimand and design differs from other ongoing clinical effectiveness studies/trials.
PROTECTOR aims to recruit another 1250 high risk women over the next 4 years.
Looking forward to work with all our collaborators and stake holders in the coming years.

[Julia Hippisley-Cox @JuliaHCox]

NEW 3-Year Postdoc Position
We’re hiring a postdoc to join a new, interdisciplinary NIHR programme focused on the design-led development and evaluation of patient-centred risk communication tools for medicine use before & during pregnancy. @NIHRresearch

https://t.co/WLgVTO0SD0

[Prof Ranjit Manchanda @ProfManchanda]

@QMUL_WIPH @QMBCI @BGCS_org @ENYGO_official @ESGO_society @IGCSociety @BgcsFellows @eveappeal

[Prof Ranjit Manchanda @ProfManchanda]

https://t.co/uUYabIrF2A
We have advertised for a Clinical Research Fellow to work in our Clinical Academic Team @wpp_wiph
@NHSBartsHealth
We run a number of studies in precision prevention of Women’s cancers
https://t.co/QYL5KlIDru
Come and join our team
Please RT

[Prof Ranjit Manchanda @ProfManchanda]

Delighted to host the @eveappeal team today at @wpp_wiph
Charterhouse sq @QMUL_WIPH
Fantastic interaction with @athenalamnisos1 , VasJames, Ian Jacobs and Christine Ekechi
@QMUL @NHSBartsHealth @QMBCI